Safety and tolerability of SER-109 as an investigational microbiome therapeutic in adults with recurrent Clostridioides difficile infection: a phase 3, open-label, single …

MD Sims, S Khanna, P Feuerstadt, TJ Louie… - JAMA Network …, 2023 - jamanetwork.com
Importance A safe and effective treatment for recurrentClostridioides difficileinfection (CDI) is
urgently needed. Antibiotics kill toxin-producing bacteria but do not repair the disrupted …

Gut Dysbiosis and Clostridioides difficile Infection in Neonates and Adults

IM Vasilescu, MC Chifiriuc, GG Pircalabioru… - Frontiers in …, 2022 - frontiersin.org
In this review, we focus on gut microbiota profiles in infants and adults colonized (CDC) or
infected (CDI) with Clostridioides difficile. After a short update on CDI epidemiology and …

Healthcare resource utilization and direct medical costs associated with index and recurrent Clostridioides difficile infection: a real-world data analysis

P Feuerstadt, L Stong, DN Dahdal… - Journal of medical …, 2020 - Taylor & Francis
Aims: This study aimed to evaluate all-cause economic outcomes, healthcare resource
utilization (HRU), and costs in patients with Clostridioides difficile infection (CDI) and …

Health care resource utilization and costs of recurrent Clostridioides difficile infection in the elderly: a real-world claims analysis

WW Nelson, TA Scott, M Boules, C Teigland… - Journal of Managed …, 2021 - jmcp.org
BACKGROUND: Clostridioides difficile infection (CDI) affected an estimated 365,000
persons in the United States in 2017. Despite a nationally decreasing trend of CDI cases …

Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota–Based …

CS Berenson, B Lashner, LY Korman… - Clinical Infectious …, 2023 - academic.oup.com
Background Although comorbidities are risk factors for recurrent Clostridioides difficile
infection (rCDI), many clinical trials exclude patients with medical conditions such as …

[HTML][HTML] Mortality, health care use, and costs of Clostridioides difficile infections in older adults

P Feuerstadt, WW Nelson, EM Drozd, J Dreyfus… - Journal of the American …, 2022 - Elsevier
Objectives Estimate mortality, cost, and health care resource utilization for Medicare
beneficiaries aged≥ 65 years who suffered a primary Clostridioides difficile infection (CDI) …

Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo …

JF Kokai-Kun, T Roberts, O Coughlin, C Le… - The Lancet infectious …, 2019 - thelancet.com
Summary Background Infections with Clostridium difficile are a health threat, yet no products
are currently licensed for prevention of primary C difficile infections. Intravenous β-lactam …

Clinical complications in patients with primary and recurrent Clostridioides difficile infection: A real-world data analysis

P Feuerstadt, M Boules, L Stong… - SAGE open …, 2021 - journals.sagepub.com
Objective: Clostridioides difficile infection and recurrent C. difficile infection result in
substantial economic burden and healthcare resource use. Sepsis and bowel surgery are …

An Updated Review of Clostridium difficile Treatment in Pediatrics

CT Campbell, MO Poisson… - The Journal of Pediatric …, 2019 - meridian.allenpress.com
Clostridium difficile infection (CDI) continues to have clinical and economic impact across all
health care settings. Pediatrics accounts for a small percentage of worldwide infection; …

[HTML][HTML] Risk factors for recurrence of Clostridioides difficile in hospitalized patients

D Alrahmany, BJ Ereshefsky, WS El Nekidy… - Journal of Infection and …, 2021 - Elsevier
Background Diarrhea and pseudomembranous colitis associated with Clostridioides difficile–
a spore-forming anaerobic Gram-positive bacillus–is a major infection in hospitalized …